CAS: 63132-39-8; (3-(Dimethylamino)-1-Hydroxypropane-1,1-Diyl)Bis(Phosphonic Acid)

该化合物是一种主要用于治疗骨骼相关疾病,特别是骨质疏松症和佩吉氏病的二磷酸化合物,抑制骨质疏松的中位骨吸附,从而有助于保持或提高骨密度.奥巴德罗酸的化学结构有两个磷酸组,对骨骼组织中的氢氧亚丙酸具有强烈的亲近性.该化合物通常通过口服施用,其特点是水溶性较低,影响其生物利用率.在安全方面,对阿巴德诺酸的潜在副作用进行了评估,这可能包括胃肠扰动,在罕见的情况下,包括海螺的骨质疏松,其药用包括吸收,分配,新陈代谢和排泄过程,而这些过程对于其治疗效果至关重要.

结构式图片

欧盟法规

C&L通报

上下游产品

3-dimethylaminopropionic acid formaldehyd pamidronate 1-amino-3-(N,N-dimethylamino)-propylidene-1,1-bisphosphonic acid

合成工艺路线路线简述

    📜N,N-二甲基-β-丙氨酸置于亚磷酸,三氯氧磷体系中,化学反应 6.5H,反应生成 奥帕膦酸钠
    参考文献:一类磺酸-膦酸配体的制备及其用途
    标题:一类磺酸-膦酸配体的制备及其用途
    摘要:本发明涉及一类磺酸‑膦酸配体的制备及其用途.该类磺酸‑膦酸配体结构中包括有磺酸,季铵和膦酸基团,具体包括磺酸甜菜碱‑膦酸配体,磺酸‑唑来膦酸配体和磺酸‑利塞膦酸配体;磺酸甜菜碱‑膦酸配体分子式为:C8H21No10P2S,分子量为384.2;磺酸‑唑来膦酸配体分子式为:C8H16O10N2P2S,分子量为394.23;磺酸‑利塞膦酸配体分子式为:C10H17O10Np2S,分子量为405.25.本发明磺酸‑膦酸配体具有极佳的亲水性,并能与多种金属元素配位.此类分子在以下两方面有重要应用:一,用于改性疏水性纳米材料,从而显著提高材料的亲水性,使其可在水相中分散;二,对肿瘤具有一定的抑制效果.

    海关参考信息

    专利信息


    专利号:EP-1566177-A1
    优先权日:2004-02-23
    标 题:The use of bisphosphonates for treating skin by stimulating of collagen synthesis
    发明人:KIM JIN; YOOK JONG IN; KIM NAM HEE; RYU JU KYOUNG
    权利人:TIGEN BIOTECH CO LTD
    摘要:The present invention relates to a novel use of bisphosphonate, and morenparticularly to a composition for increasing collagen synthesis comprisingnbisphosphonate as an active ingredient, as well as the use thereof. The inventivencomposition comprising the bisphosphonate promotes collagen synthesis, and thus, whennit is applied to the skin, it reduces wrinkles of the skin and makes the skin elastic. Fornthis reason, the inventive composition will be useful as cosmetics for the prevention ornimprovement of skin aging or a wound-healing agent. Furthermore, the inventivencomposition can remarkably increase the collagen synthesis of fibroblasts in vitro , andnthus, can be effectively used in the production of products containing collagen.

    专利号:US-8017776-B2
    优先权日:2003-07-15
    标题 :Methods for synthesis of acyloxyalkyl compounds
    发明人:BHAT LAXMINARAYAN; GALLOP MARK A
    权利人:XENOPORT INC
    摘要:Disclosed herein are methods for synthesizing 1-(acyloxy)-alkyl prodrug derivatives of drugs through oxidation of 1-acyl-alkyl derivatives of drugs under anhydrous reaction conditions. The methods typically proceed stereospecifically, in high yield, do not require the use of activated intermediates and/or toxic compounds and are readily amenable to scale-up.

    专利号:US-8143437-B2
    优先权日:2002-02-19
    标题:Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
    发明人:GALLOP MARK A; XIANG JIA-NING; YAO FENMEI; BHAT LAXMINARAYAN; ZHOU CINDY X
    权利人:GALLOP MARK A; XIANG JIA-NING; YAO FENMEI; BHAT LAXMINARAYAN; ZHOU CINDY X; XENOPORT INC
    摘要:The present invention provides a method for synthesizing 1-(acyloxy)-alkyl derivatives from 1-acyl-alkyl derivatives, which typically proceeds stereospecifically, in high yield, does not require the use of activated intermediates and/or toxic compounds and is readily amendable to scale-up. The current invention also provides 1-acyl-alkyl derivatives of known drug components and methods for synthesizing these 1-acyl-alkyl derivatives.

    专利号:WO-2008058722-A1
    优先权日:2006-11-16
    标 题:Reagent and use thereof for the production of bisphosphonates
    发明人:LERSTRUP KNUD; PREIKSCHAT HERBERT FRITZ; FISCHER ERIK
    权利人:SANDOZ AS; LERSTRUP KNUD; PREIKSCHAT HERBERT FRITZ; FISCHER ERIK
    摘要:A new liquid reagent is disclosed in form of an ionic liquid containing phosphorous acid and a tertiary amine. The reagent can be used as a replacement of phosphorous acid, where the new reagent as a liquid reagent can be handled using usual equipment for handling liquids and the dosing of the reagent can therefore be controlled more precisely in industrial plants compared to phosphorous acid, which is a solid at ambient temperature. The new liquid reagent is particular suitable for the synthesis of bisphosphonates.

    专利号:US-2006287257-A1
    优先权日:2005-06-20
    标 题 :Pharmaceutical compositions to treat diseases caused by mycobacterium
    发明人:STOCKEL RICHARD F
    权利人:STOCKEL RICHARD F
    摘要:The invention teaches the synthesis of pharmaceutical composition and methods of synthesis to treat people and animals infected with a pathogenic mycobacterium. In particular the compositions of this invention are suitable for the treatment of tuberculosis, malaria, and other infections diseases caused by mycobacterium.

    专利号:US-8183409-B2
    优先权日:2004-05-06
    标题:High yield and rapid synthesis methods for producing metallo-organic salts
    发明人:CHRISTGAU STEPHAN; ANDERSEN JENS E T
    权利人:CHRISTGAU STEPHAN; ANDERSEN JENS E T; OSTEOLOGIX AS
    摘要:A new method for preparing salts of metal cations and organic acids, especially divalent salts of alkaline earth metal ions from group II of the periodic system and carboxylic acids. The method comprising the use of a high temperature (about 90° or more) and, optionally. high pressure, in order to obtain a higher yield, purity and faster reaction speed than obtained with known synthesis methods. In particular, the present invention relates to the production of strontium salts of carboxylic acids. Novel strontium salts are also provided by the present method.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Roldán EJ. [Pamidronate and olpadronate discoverer, Prof. Olav Maria Leonard Bijvoet passed away]. Medicina (B Aires). 2014;74(5):425-7. Spanish. doi: 10.1016/j.abb.2010.12.013. Epub 2010 Dec 15. doi: 10.1016/j.jcms.2010.03.014. Epub 2010 Apr 27. doi: 10.1902/jop.2008.070168 . Epub 2007 Apr 8. Epub 2007 Feb 17. Review. Epub 2002 Dec 10. Epub 2002 Feb 15.

    合成参考文献


    参考文献:10.1021/jm0303709
    摘要:Sanders JM, Ghosh S, Chan JM, Meints G, Wang H, Raker AM, Song Y, Colantino A, Burzynska A, Kafarski P, Morita CT, Oldfield E. Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates. J Med Chem. 2004 Jan 15;47(2):375–84. doi: 10.1021/jm0303709.
    参考文献:10.2165/00126839-199901030-00002
    摘要:Peters DC, Coleman SG. Osteoporosis. Summary and table. Drugs R D. 1999 Mar;1(3):203–9. doi: 10.2165/00126839-199901030-00002.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知